Insider · CIK 0001701440
Luke Nathaniel Walker
Files at ZNTL (Zentalis Pharmaceuticals, Inc.), CNTX (Context Therapeutics Inc.). First filing -, latest -.
Luke Nathaniel Walker files SEC Form 4 as director at ZNTL (Zentalis Pharmaceuticals, Inc.), and also at CNTX (Context Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Luke Nathaniel Walker has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | CNTX Context Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 26, 2026 |
| Jun 16, 2026 | ZNTL Zentalis Pharmaceuticals, Inc. | AGrant or award Common Stock | +57,100 | $0.00 | $0 | 201,384 | Jun 18, 2026 |
| Jun 17, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | AGrant or award Common Stock | +57,603 | $0.00 | $0 | 144,284 | Jun 18, 2025 |
| Jun 12, 2025 | CNTX Context Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +123,500 | $0.00 | $0 | 123,500 | Jun 12, 2025 |
Questions about Luke Nathaniel Walker
Answered from the filings on this page, as of the latest one.
Is Luke Nathaniel Walker buying or selling?
Luke Nathaniel Walker has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Luke Nathaniel Walker's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Luke Nathaniel Walker has 0.
Where does Luke Nathaniel Walker file Form 4?
Luke Nathaniel Walker has filed Form 4 at ZNTL (Zentalis Pharmaceuticals, Inc.); CNTX (Context Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.